Clinical Evidence
Please select a section from the list below:
- Summary of Data - Overview of data published plus an introduction to the application of serum free light chain assays
- Initial Screening Investigation - The addition of serum free light chain assays to SPE increases the detection of B cell dyscrasia
- Prognosis - Help identify patients with a high risk of progression and poor prognosis
- Nonsecretory MM - Freelite serum free light chains can be detected in 82% of NSMM patients
- Light Chain MM - Freelite is a suitable alternative to 24-hour urine testing for Bence Jones Protein
- AL Amyloidosis - "Serum free light chain assay is required for investigation in suspected AL amyloid"
- Intact Immunoglobulin MM and LCE (Light Chain Escape) - 96% of IIMM patients have abnormal light chain concentrations or kappa/lambda ratio
- MGUS - Freelite enables risk stratification of MGUS patients *
- Renal Disease - Quickly identify patients at risk of kidney damage
- Other Free Light Chain Diseases - Solitary plasmacytoma of bone, Waldenstrom's macroglobulinaemia, B-cell, non-Hodgkin lymphomas, B-cell chronic lymphocytic leukaemia
- Monitoring Treatment & Disease - Freelite offers a sensitive indicator of patient status in treatment and remission
- Interpretation of Results - A guide to understanding high, low and normal kappa and lambda levels and kappa/lambda ratio
- Publications available to order - A list of published Freelite references available to order from Binding Site
If you have any questions about Freelite which are not covered here please see our FAQ section or contact us.
* In the USA diagnostic use of this product is restricted to those stated in the product insert
